For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

AbbVie offers a strong bullish outlook with rising earnings, dividends, and technical signals. Read here for an analysis of ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...

AbbVie leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira, an analyst said Friday as ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Discover AbbVie's Q3 2025 earnings: strong EPS, raised guidance, robust pipeline, and growth drivers like Skyrizi and Rinvoq.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.